Compositions and methods for treating lung inflammation

Patent metadata

Field	Value
Publication number	US-11767520-B2
Application number	US-201816499979-A
Country	US
Kind code	B2
Filing date	Apr 19, 2018
Priority date	Apr 20, 2017
Publication date	Sep 26, 2023
Grant date	Sep 26, 2023

Abstract

Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.

First claim

The invention claimed is:

1. A method of increasing serum concentration of a histidyl-tRNA synthetase (HRS)-Fc fusion polypeptide in a subject, comprising administering to the subject the HRS-Fc fusion polypeptide in combination with pirfenidone, wherein the HRS-Fc fusion polypeptide comprises, consists, or consists essentially of SEQ ID NO: 157.

2. The method of claim 1 , wherein the pirfenidone increases the serum concentration of the HRS-Fc fusion polypeptide in the subject by at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, or 200% or more relative to the HRS-Fc fusion polypeptide alone.

3. The method of claim 1 , wherein the pirfenidone is administered at an individual dosage unit that ranges from about 50 to about 1000 mg, or an individual dosage unit of about no more than about, or at least about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 10, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 mg, optionally in 1, 2, or 3 capsules for oral dosing.

4. The method of claim 1 , wherein the pirfenidone is administered at a daily dosage unit that ranges from about 100 to about 4000 mg/day, or a daily dosage unit of about, no more than about, or at least about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 10, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, or 4000 mg/day, optionally in about 1, 2, 3, 4, 5, 6, 7, 8, 9 capsules for oral dosing.

5. The method of claim 1 , wherein the pirfenidone is administered at an individual dosage unit of about 800 mg (e.g., 801 mg), optionally as three approximately 267 mg capsules for oral dosing, taken as three capsules per individual dosage.

6. The method of claim 1 , wherein the pirfenidone is administered at daily dosage unit of about 2400 mg/day (e.g., 2403 mg/day), optionally as nine approximately 267 mg capsules for oral dosing three times daily, taken as three capsules per individual dosage.

7. The method of claim 1 , wherein the subject has lung inflammation.

8. The method of claim 7 , which improves one or more of the clinical symptoms or parameters of the lung inflammation in the subject in need thereof.

9. The method of claim 8 , wherein the one or more clinical symptoms or parameters are selected from one or more of lung fibrosis, inflammatory cell infiltrates in the lung, respiratory function, and body weight.

10. The method of claim 7 , wherein the subject has or is risk for having an interstitial lung disease (ILD).

11. The method of claim 10 , wherein the ILD is idiopathic or associated with a connective tissue disease, an autoimmune disease, exposure to inhaled substances or drug(s), an infection, or a malignancy.

12. The method of claim 11 , wherein the ILD is selected from or is associated with one or more of idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, sarcoidosis, Hammann-Rich syndrome, Antisynthetase syndrome, idiopathic eosinophilic pneumonia, alveolar hemorrhage syndrome, pulmonary alveolar proteinosis, asbestosis, silicosis, berylliosis, rheumatoid arthritis, lupus erythematosus, chronic graft vs host disease with pulmonary involvement, sclerosis (systemic) or scleroderma, polymyositis, dermatomyositis, chronic pulmonary disease, asthma, bronchitis (respiratory bronchitis), pneumonia, hypersensitivity pneumonitis, chronic hypersensitivity pneumonia, respiratory distress syndrome, Still's disease, acute lung injury, microscopic polyangitis, pulmonary edema, pulmonary Langerhans cell histiocytosis, acute inhalational exposures, drug-induced lung disease, desquamative interstitial pneumonia, and/or cystic fibrosis.

Assignees

• Atyr Pharma Inc

Inventors

• Mendlein John D
• Ogilvie Kathleen

Classifications

• C12N9/93 Primary

  Ligases (6) · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61K9/5123

  Organic compounds, e.g. fats, sugars · CPC title

• A61K31/4418

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title